1NHS Lothian, Edinburgh, UK
Breast Cancer Research 25(S1): P27
Introduction: We present our audit of 238 wireless localisations, also patient feedback results. We outline our transformational plans for localisation at recall assessment and the potential resource efficiencies/patient benefits we have extrapolated from our data.
Results:
Localisation audit:
101 saviscout, 137 magseed excisions.
128 were screen detected.
Overall re-excision rate—16.8%, 14.8% for screening cases.
Patient experience was positive.
One hundred and two (43%) met proposed suitability criteria (unifocal, unequivocally malignant) for localisation at recall assessment.
Localisation of appropriate lesions at screening recall biopsy will commence in August 2022. We extrapolate the following:
323 localisations annually would be appropriate for localisation at recall biopsy.
Symptomatic US appointment savings (15 min per localisation): 81 h.
Vetting/reviewing of localisation requests (10 min per case): 54 h.
(Overall saving of 135 DCC hours of consultant time).
Radiographic post-insertion film acquisition time saving (15 min per case): 81 h.
A&C appointing/booking time (15 min per case) 81 h.
Cost-savings of markers (30.87 per marker): £9971.01.
Three hundred and twenty-three patients would be spared a second procedure, remote from their home address, with risk of confusion over localisation and operative date eliminated.
In September 2022, appointments previously allocated to localisations at our institution will be reallocated to new patient imaging generating 30 weekly slots (a full NPC) of extra imaging capacity with no additional resource.
Conclusion: Wireless localisation is an effective and acceptable localisation method. Localisation at recall biopsy presents an opportunity for significant efficiency gains, marker cost savings and patient benefits.